Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Alnylam Restructures, Cuts 33% of Workforce | Contract Pharma

What are you searching for?

Sign in
Breaking News

Alnylam Restructures, Cuts 33% of Workforce

Will focus on RNAi therapeutic product strategy

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Alnylam Pharmaceuticals will implement a strategic corporate restructuring, eliminating approximately 33% of its workforce to focus resources on its Alnylam 5×15 RNAi therapeutic product strategy and ALN-TTR for the treatment of transthyretin-mediated amyloidosis (ATTR) and ALN-APC for the treatment of hemophilia, as well as other pipeline programs with existing alliances and new partnerships. Alnylam expects to save approximately $20 million in 2012 and will incur one-time restructuring costs of approximately $4 million.

John Maraganore, Ph.D., chief executive officer of Alnylam, commented, “We have made remarkable progress in advancing RNAi therapeutics as a new class of innovative medicines, including recent results demonstrating human proof of concept in our ALN-TTR program and clinical efficacy for RNAi therapeutics in our ALN-PCS program. As we effect our ongoing transformation from a platform company to a product company, now is the time to focus our near-term efforts and resources on what we believe to be our highest value opportunities, while advancing other pipeline programs through existing alliances and new partnerships that we aim to form in the future.”

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters